Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?

  • Abstract
  • References
  • Similar Papers
Abstract
Translate article icon Translate Article Star icon
Take notes icon Take Notes

Recombinant human serum albumin: a true therapeutic substitute or merely a serum level elevator?

Note: looks like a niche area of research and we don't have enough papers to generate a graph.
ReferencesShowing 7 of 7 papers
  • 10.1007/s12072-025-10912-5
Comment on "CT-based intratumoral and peritumoral radiomics to predict the treatment response to hepatic arterial infusion chemotherapy plus lenvatinib and PD-1 in high-risk hepatocellular carcinoma cases: a multi-center study".
  • Sep 15, 2025
  • Hepatology international
  • Zhiyao Shi + 3 more

  • Open Access Icon
  • Cite Count Icon 543
  • 10.1002/hep.31884
Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases.
  • Aug 1, 2021
  • Hepatology (Baltimore, Md.)
  • Scott W Biggins + 7 more

  • 10.1007/s12072-025-10871-x
A randomized, phase Ib trial of recombinant human serum albumin in cirrhotic patients with ascites.
  • Jul 23, 2025
  • Hepatology international
  • Xinrui Wang + 30 more

  • Open Access Icon
  • Cite Count Icon 412
  • 10.1016/s0140-6736(18)30840-7
Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial
  • Jun 1, 2018
  • The Lancet
  • Paolo Caraceni + 92 more

  • Open Access Icon
  • Cite Count Icon 6
  • 10.1016/j.xcrm.2023.101345
Synthetically mannosylated antigens induce antigen-specific humoral tolerance and reduce anti-drug antibody responses to immunogenic biologics
  • Dec 20, 2023
  • Cell reports. Medicine
  • Rachel P Wallace + 14 more

  • 10.1136/gutjnl-2025-336092
New frontier in albumin replacement therapy.
  • Jul 22, 2025
  • Gut
  • Rajiv Jalan + 1 more

  • 10.1136/gutjnl-2025-335651
Performance of the China-CLIF framework in acute-on-chronic liver failure: a multicohort study across all aetiologies.
  • Jul 25, 2025
  • Gut
  • Jinjin Luo + 53 more

More from: Hepatology international
  • New
  • Research Article
  • 10.1007/s12072-025-10946-9
hnRNPA3 promotes the proliferation of hepatocellular carcinoma cells by stabilizing GLI2 proteins and activating Hedgehog pathway.
  • Nov 5, 2025
  • Hepatology international
  • Xuesi Tian + 8 more

  • New
  • Discussion
  • 10.1007/s12072-025-10952-x
Comment on "Immunomodulation by bepirovirsen may induce killing of infected hepatocytes (B-Together study)".
  • Nov 4, 2025
  • Hepatology international
  • S Dhanya Dedeepya + 2 more

  • New
  • Research Article
  • 10.1007/s12072-025-10940-1
SOX9 promotes hepatocyte proliferation via upregulating TGF-α expression during liver regeneration.
  • Nov 3, 2025
  • Hepatology international
  • Shu-Qing Liu + 12 more

  • New
  • Discussion
  • 10.1007/s12072-025-10950-z
Integrating mental health into MASLD prevention.
  • Nov 3, 2025
  • Hepatology international
  • Changlong Yang + 2 more

  • New
  • Discussion
  • 10.1007/s12072-025-10948-7
Methodological considerations in linking depression to metabolic dysfunction-associated steatotic liver disease: insights for future study design.
  • Nov 1, 2025
  • Hepatology international
  • Zheng Han

  • New
  • Discussion
  • 10.1007/s12072-025-10947-8
Enhancing the understanding and management of metabolic dysfunction-associated steatotic liver disease in colorectal cancer patients: insights and future directions.
  • Oct 29, 2025
  • Hepatology international
  • Zhexian Liu + 1 more

  • New
  • Discussion
  • 10.1007/s12072-025-10942-z
Author Response to "Letter to the Editor": "Critical flaws in the predictive model for bacterial infections in older AoCLD patients".
  • Oct 28, 2025
  • Hepatology international
  • Ju Zou + 1 more

  • New
  • Front Matter
  • 10.1007/s12072-025-10943-y
Depression and MASLD: a shared burden of mind and metabolism.
  • Oct 27, 2025
  • Hepatology international
  • Mohit Varshney + 1 more

  • Discussion
  • 10.1007/s12072-025-10941-0
Reply to: A commentary on "Safety of tenofovir alafenamide in the context of hyperlipidemia and cardiovascular diseases: a nationwide analysis".
  • Oct 25, 2025
  • Hepatology international
  • Jae-Young Kim + 4 more

  • Research Article
  • 10.1007/s12072-025-10939-8
p53 regulates glucose metabolic reprogramming in MASLD-related hepatocellular carcinoma via modulating mitochondrial pyruvate carriers.
  • Oct 25, 2025
  • Hepatology international
  • Ze Wang + 7 more

Save Icon
Up Arrow
Open/Close
  • Ask R Discovery Star icon
  • Chat PDF Star icon

AI summaries and top papers from 250M+ research sources.

Search IconWhat is the difference between bacteria and viruses?
Open In New Tab Icon
Search IconWhat is the function of the immune system?
Open In New Tab Icon
Search IconCan diabetes be passed down from one generation to the next?
Open In New Tab Icon